Protagonist Therapeutics (PTGX) Equity Ratio (2015 - 2026)

Protagonist Therapeutics has disclosed Equity Ratio across 12 years of filings, most recently posting 0.94 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.94, up 1.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (up 1.22% YoY), and the FY2025 annual result was 0.92, up 1.45% from the prior year.
• Equity Ratio came in at 0.94 for Q1 2026 at Protagonist Therapeutics, up from 0.92 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.94 in Q4 2023 to a low of 0.86 in Q2 2022.
• The 5-year median for Equity Ratio is 0.91 (2024), against an average of 0.9.
• Across the five-year window, Equity Ratio increased 8.16% in 2023 and retreated 4.02% in 2024, its largest moves.
• Protagonist Therapeutics' Equity Ratio stood at 0.87 in 2022, then grew by 8.16% to 0.94 in 2023, then declined by 3.59% to 0.91 in 2024, then grew by 1.45% to 0.92 in 2025, then climbed by 2.16% to 0.94 in 2026.
• The last three Equity Ratio figures came in at 0.94 (Q1 2026), 0.92 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.